Skip to main content
NEXTBIOMEDICAL Co., Ltd. logo

NEXTBIOMEDICAL Co., Ltd. — Investor Relations & Filings

Ticker · 389650 ISIN · KR7389650003 KO Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2024-08-06 Capital/Financing Update
Country KR South Korea
Listing KO 389650

About NEXTBIOMEDICAL Co., Ltd.

https://nextbiomedical.co.kr/en/

NEXTBIOMEDICAL Co., Ltd. is a company specializing in the development and commercialization of innovative therapeutic solutions, with a focus on drug-device combination products. The company's core competency is its proprietary polymer technology platform, which includes biodegradable adhesive polymers and resorbable microspheres. These technologies are applied to create first-in-class medical devices that address unmet clinical needs. Key product applications include advanced hemostatic agents for endoscopic procedures and embolic materials for interventional pain management and vascular therapies, such as genicular artery embolization for osteoarthritis pain.

Recent filings

Filing Released Lang Actions
[기재정정]투자설명서
Capital/Financing Update Classification · 1% confidence The document is a '정정신고서' (Amendment Report) for an '투자설명서' (Prospectus) filed by NextBioMedical. It details changes to the public offering price, total offering amount, and allocation ratios for a KOSDAQ listing. This is a formal regulatory filing related to a securities offering, which falls under the category of Regulatory Filings (RNS) as it is a specific type of legal/regulatory document that does not fit into the other specialized categories like 10-K, ER, or IP.
2024-08-06 Korean
투자설명서
Capital/Financing Update Classification · 1% confidence The document is a 'Securities Registration Statement' (투자설명서) for NextBiomedical, detailing a public offering of 1,000,000 shares. It includes specific offering prices, subscription periods, payment dates, and detailed risk factors (business and company risks) associated with the offering. This is a formal regulatory filing required for an IPO or capital raise in South Korea, which falls under the category of a Prospectus/Securities Registration Statement. Given the provided categories, 'Regulatory Filings' (RNS) is the most appropriate fallback for this type of formal registration document.
2024-08-02 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) for Next Biomedical Co., Ltd. It details specific amendments made to a previously filed registration statement, including updates to investment risk factors and financial data. In the context of financial filings, a Securities Registration Statement (and its amendments) is a regulatory document required for public offerings or listings, which falls under the 'Regulatory Filings' category as it does not fit into the specific categories like 10-K, ER, or others provided.
2024-08-01 Korean
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment filed by Next Biomedical Co., Ltd. It explicitly details changes to the public offering schedule, including demand forecasting, subscription dates, and payment dates, following previous filings. This is a formal regulatory filing required for equity offerings in South Korea, which falls under the 'Regulatory Filings' category as it is a specific legal document for securities registration and amendment.
2024-07-11 Korean
[기재정정]증권신고서(지분증권)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서(지분증권) 정정신고' (Amendment to Securities Registration Statement for Equity Securities) filed by NextBiomedical. It details changes to the public offering schedule, subscription dates, and other procedural information related to a stock issuance. In the context of financial filings, a Securities Registration Statement (and its amendments) is a primary regulatory document for capital raising, which falls under the 'Capital/Financing Update' category.
2024-06-27 Korean
증권신고서(지분증권)
Capital/Financing Update Classification · 1% confidence The document is a '증권신고서' (Securities Registration Statement) filed by '주식회사 넥스트바이오메디컬' with the Financial Services Commission (FSC) in South Korea. It details the offering of 1,000,000 shares of common stock, includes investment risk factors, and provides information required for a public offering (IPO) under the Capital Markets Act. This is a formal regulatory filing for a securities offering, which falls under the 'Regulatory Filings' category as it is a primary registration document for capital raising.
2024-06-10 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.